Education
About Us
Working with TipRanks
Follow Us
Island Pharmaceuticals Ltd (AU:ILA)
ASX:ILA
ILA Stock Chart & Stats
AU$0.44
<AU$0.01(1.74%)
At close: 4:00 PM EST
AU$0.44
<AU$0.01(1.74%)
Day’s Range― - ―
52-Week RangeAU$0.12 - AU$0.63
Previous CloseN/A
Volume208.69K
Average Volume (3M)781.24K
Market Cap
AU$144.44M
Enterprise ValueAU$104.41M
Total Cash (Recent Filing)AU$6.87M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.68
Next Earnings
Aug 20, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding294,766,700
10 Day Avg. Volume388,484
30 Day Avg. Volume781,243
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)3.39
Price to Sales (P/S)204.10
P/FCF Ratio-8.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong SolvencyZero reported debt and materially higher equity provide durable solvency and financial flexibility. This low-leverage position reduces default risk, supports ongoing R&D spending, and gives management optionality to fund trials or partnerships without immediate liquidity distress.
Focused Antiviral R&D StrategyA clear strategic focus on antiviral therapeutics concentrates resources and expertise, improving pipeline prioritization and R&D efficiency. Structural demand for antivirals and a targeted pipeline increase the chance that successful clinical outcomes yield outsized commercial value long term.
Improving Cash Burn TrendA modest reduction in cash burn versus the prior year suggests early operational improvements or milestone-driven funding. If sustained, this trend can extend runway, reduce near-term financing needs and improve chances of reaching value-driving development milestones without immediate dilution.
Bears Say
Persistent Cash BurnMaterial negative operating cash flow highlights ongoing reliance on external financing. Persistent cash burn constrains the firm's ability to fund clinical programs internally, raises dilution risk, and can force postponement of strategic initiatives if new capital is delayed or expensive.
Sharp Revenue DeclineA ~70% revenue drop and a large net loss indicate weak commercial traction or one-time setbacks. Such volatile and contracting revenue undermines predictability for R&D funding and scaling, making it harder to plan long-term investments and secure favorable partner or investor terms.
Negative Returns / Dilution RiskContinuing negative returns on equity imply shareholder value erosion from operating losses. Even with low debt, the company will likely need additional equity financing, which dilutes existing holders and can pressure management toward short-term capital raises over strategic, value-maximizing decisions.
Island Pharmaceuticals Ltd News
ILA FAQ
What was Island Pharmaceuticals Ltd’s price range in the past 12 months?
Island Pharmaceuticals Ltd lowest share price was AU$0.12 and its highest was AU$0.63 in the past 12 months.
What is Island Pharmaceuticals Ltd’s market cap?
Island Pharmaceuticals Ltd’s market cap is AU$144.44M.
When is Island Pharmaceuticals Ltd’s upcoming earnings report date?
Island Pharmaceuticals Ltd’s upcoming earnings report date is Aug 20, 2026 which is in 160 days.
How were Island Pharmaceuticals Ltd’s earnings last quarter?
Island Pharmaceuticals Ltd released its earnings results on Feb 19, 2026. The company reported -AU$0.019 earnings per share for the quarter, missing the consensus estimate of -AU$0.005 by -AU$0.014.
Is Island Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Island Pharmaceuticals Ltd’s price is currently Overvalued.
Does Island Pharmaceuticals Ltd pay dividends?
Island Pharmaceuticals Ltd does not currently pay dividends.
What is Island Pharmaceuticals Ltd’s EPS estimate?
Island Pharmaceuticals Ltd’s EPS estimate is -0.01.
How many shares outstanding does Island Pharmaceuticals Ltd have?
Island Pharmaceuticals Ltd has 294,766,700 shares outstanding.
What happened to Island Pharmaceuticals Ltd’s price movement after its last earnings report?
Island Pharmaceuticals Ltd reported an EPS of -AU$0.019 in its last earnings report, missing expectations of -AU$0.005. Following the earnings report the stock price went up 1.351%.
Which hedge fund is a major shareholder of Island Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in AU:ILA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Island Pharmaceuticals Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ILA Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$76.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
-90.37%
Trailing 12-Months
Asset Growth
192.19%
Trailing 12-Months
Company Description
Island Pharmaceuticals Ltd
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing approximately four and a half thousand molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101. The company was founded in 2017 and is based in Camberwell, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Prescient Therapeutics Limited
―
Starpharma Holdings Limited
―
AnteoTech Ltd
―
Neuroscientific Biopharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---